Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 See also  





2 References  














Corticosteroid-induced lipodystrophy







Add links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


Corticosteroid-induced lipodystrophy
SpecialtyDermatology

Corticosteroid-induced lipodystrophy (CIL) is a condition of abnormal fat deposition caused by corticosteroid medications.[1] Fat accumulates in the facial area ("moon face"), dorsocervical region ("buffalo hump"), and abdominal area ("pot belly" or "beer belly"), whereas the thickness of subcutaneous fat in the limbs is decreased.[1] The resulting appearance has been described as "Cushingoid",[1] in relation to the fact that it also occurs in individuals with Cushing's syndrome (abnormally high cortisol levels).[2] The condition is considered by patients to be the most distressing side effect caused by corticosteroids.[1]

Short-term therapy (<3 months) with 10 to 30 mg/day of a prednisone equivalent has been reported to be associated with Cushingoid traits in 15 to 40%.[1] Long-term therapy (>3 months) with corticosteroids has been associated with Cushingoid features in 32 to 83% of individuals.[1] However, these symptoms have mostly been diagnosed in a subjective and observer-dependent manner.[1] In a prospective study, the cumulative incidence of CIL with high-dose prednisone therapy was found to be 61% after 3 months, 65% after 6 months, 68% after 9 months, and 69% after 12 months.[1] One study found that even a very low dosage of prednisone of 5 mg/day was associated with symptoms of "Cushing's syndrome".[1] It has been said that data on risk factors for CIL, such as corticosteroid dosage or duration of therapy, is surprisingly sparse.[1] Possible risk factors for CIL include high residual cortisol secretion, decreased clearance of corticosteroids, female sex, younger age (<50 years), high initial body-mass index, and high caloric intake.[1]

CIL has been found to be usually reversible at prednisone-equivalent dosages of less than 10 mg/day.[1]Alow-calorie diet may be considered to limit the risk of CIL or to attempt to reverse it.[1] CIL is not merely an aesthetic adverse effect, as it has been associated with features of metabolic syndrome such as insulin resistance, dyslipidemia, and high blood pressure.[1]

See also[edit]

References[edit]

  1. ^ a b c d e f g h i j k l m n Fardet L, Kassar A, Cabane J, Flahault A (2007). "Corticosteroid-induced adverse events in adults: frequency, screening and prevention". Drug Saf. 30 (10): 861–81. doi:10.2165/00002018-200730100-00005. PMID 17867724. S2CID 23041162.
  • ^ Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A (July 2016). "Complications of Cushing's syndrome: state of the art" (PDF). Lancet Diabetes Endocrinol. 4 (7): 611–29. doi:10.1016/S2213-8587(16)00086-3. hdl:11573/869810. PMID 27177728. S2CID 4915463.

  • t
  • e

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=Corticosteroid-induced_lipodystrophy&oldid=1189118943"

    Categories: 
    Corticosteroids
    Cutaneous conditions
    Symptom stubs
    Hidden categories: 
    Articles with short description
    Short description matches Wikidata
    All stub articles
     



    This page was last edited on 9 December 2023, at 20:57 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki